Nurexone Biologic Inc (NRXBF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,766 | -6,384 | -4,989 | -3,524 | -1,678 |
| Depreciation Amortization | 56 | 185 | 132 | 85 | 43 |
| Other Working Capital | 32 | 372 | 565 | 760 | 336 |
| Other Operating Activity | 442 | 1,316 | 955 | 626 | 313 |
| Operating Cash Flow | $-1,236 | $-4,511 | $-3,337 | $-2,053 | $-986 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2 | -55 | -46 | -34 | -32 |
| Investing Cash Flow | $-2 | $-55 | $-46 | $-34 | $-32 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 633 | 5,856 | 675 | 603 | 913 |
| Other Financing Activity | -8 | -22 | 2,887 | 1,897 | -3 |
| Financing Cash Flow | $625 | $5,834 | $3,562 | $2,500 | $910 |
| Exchange Rate Effect | -15 | 170 | 104 | 115 | -4 |
| Beginning Cash Position | 2,138 | 700 | 700 | 700 | 700 |
| End Cash Position | 1,510 | 2,138 | 983 | 1,228 | 588 |
| Net Cash Flow | $-628 | $1,438 | $283 | $528 | $-112 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,236 | -4,511 | -3,337 | -2,053 | -986 |
| Capital Expenditure | -2 | -55 | -46 | -34 | -32 |
| Free Cash Flow | -1,238 | -4,566 | -3,383 | -2,087 | -1,018 |